Erythropoietin update 2011

Medical Science Monitor

Volumn 17, Issue 11, 2011, Pages 240-247

  Kowalczyk, Mariusz ^a   Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anemia; Erythropoiesis stimulating agents; Erythropoietin; Erythropoietin receptor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN DELTA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY DISEASE; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM CELL; ERYTHROID PRECURSOR CELL; HEAD AND NECK CANCER; HEADACHE; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HUMAN; HYPERTENSION; IRON THERAPY; KIDNEY CELL; LUNG EMBOLISM; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; RENAL PROTECTION; SIDE EFFECT; THROMBOSIS; VASCULAR RESISTANCE;

EID: 80355149268     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.882037     Document Type: Article

References (108)

1. Malyszko J, Zbroch E, Malyszko J et al: The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci, 2010; 6: 539-44
2. Kowalczyk M, Banach M, Rysz J: Ferumoxytol: a new era of iron def-ciency anemia treatment for patients with chronic kidney disease. J Nephrol, 2011;doi: 10.5301/jn.5000025.
3. Elshamaa MF, Sabry S, Mokhtar I et al: Aluminium and lead abnormalities in children on haemodialysis: relationship with some medications. Arch Med Sci, 2010; 6: 420-29
4. Drueke TB, Locatelli F, Clyne N et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 2006; 355: 2071-84
5. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev, 1992; 72: 449-89
6. Tkocz M, Kupajski M, Duda D, Witosińska-Walica A: Spontaneous sub-capsular kidney haemorrhage - the frst symptom of renal cell carcinoma. Arch Med Sci, 2009; 5: 107-10
7. Bachmann S, Le Hir M, Eckardt KU: Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fbroblasts produce erythropoietin. J Histochem Cytochem, 1993; 41: 335-41
8. Fried W, Kilbridge T, Krantz S et al: Studies on extrarenal erythropoi-etin. J Lab Clin Med, 1969; 73: 244-48
9. Rankin EB, Biju MP, Liu Q, et al: Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest, 2007; 117: 1068-77
10. Nair DR, Mehta S, Mikhailidis DP: Assessing renal function - searching for the perfect marker continues! Arch Med Sci, 2011; 7: 565-67
11. Haase VH: Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol, 2010; 299: F1-F13
12. Jones SS, D'Andrea AD, Haines LL, Wong GG: Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood, 1990; 76: 31-35
13. Bodo E, Kromminga A, Funk W et al: Human hair follicles are an extra-renal source and a nonhematopoietic target of erythropoietin. FASEB Journal, 2007; 21: 3346-54
14. Lubas A, Zelichowski G, Próchnicka A et al: Renal autoregulation in medical therapy of renovascular hypertension. Arch Med Sci, 2010; 6: 912-18
15. Monge Naldi A, Gassmann M, Bodmer D: Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear. Cell Mol Life Sci, 2009; 66: 3595-99
16. Urao N, Okigaki M, Yamada H et al: Erythropoietin-mobilized endo-thelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006; 98: 1405-13
17. Tanner H, Moschovitis G, Kuster GM et al: The prevalence of anemia in chronic heart failure. Int J Cardiol, 2002; 86: 115-21
18. Mujib M, Desai R, Levitan EB et al: Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction. Arch Med Sci, 2010; 6: 686-88
19. Tang YD, Katz SD: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation, 2006; 113: 2454-61
20. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation, 2003; 107: 223-25
21. Anand I, McMurray JJ, Whitmore J et al: Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004; 110: 149-54
22. Ngo K, Kotecha D, Walters JA et al: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev, 2010; (1): CD007613
23. Lawler PR, Filion KB, Eisenberg MJ: Correcting Anemia in Heart Failure: The Effcacy and Safety of Erythropoiesis-Stimulating Agents. J Card Fail, 2010; 16: 649-58
24. Desai A, Lewis E, Solomon S et al: Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail, 2010; 12: 936-42
25. Foley RN, Roberts TL, Liu JN et al: Mortality from Cancer among US Hemodialysis Patients, 1995-2005. Am J Nephrol, 2010; 31: 518-26
26. Sethi A, Arora RR: Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci, 2009; 5: 3-9
27. Banach M, Rysz J: Current problems in hypertension and nephrology. Expert Opin Pharmacother, 2010; 11: 2575-78
28. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis. Clin J Am Soc Nephrol, 2009; 4: 755-62
29. Comin-Colet J, Ruiz S, Cladellas M et al: A Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome: Infuence on Neurohormonal Activation and Clinical Outcomes. J Card Fail, 2009; 15: 727-35
30. Stasi R, Abriani L, Beccaglia P et al: Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer, 2003; 98: 1786-801
31. Smolińska K, Paluszkiewicz P: Risk of colorectal cancer in relation to frequency and total amount of red meat consumption. Systematic review and meta-analysis. Arch Med Sci, 2010; 6: 605-10
32. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med, 2004; 116: 11S-26S
33. Bohlius J, Wilson J, Seidenfeld J et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 2006; 3: CD003407
34. Diskin CJ, Stokes TJ, Dansby LM et al: Beyond Anemia: The Clinical Impact of the Physiologic Effects of Erythropoietin. Seminars in Dialysis, 2008; 21: 447-54
35. Zemanek D, Veselka J, Adla T et al: Uncommon cause of obstruction in the left ventricular outfow tract by a metastasis of adenocarcinoma. Arch Med Sci, 2010; 6: 981-83
36. Chandra M, Miller ME, Garcia JF et al: Serum immunoreactive eryth-ropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron, 1985; 39: 26-29
37. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol, 2003; 4: 459-60
38. Henke M, Laszig R, Rube C et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 2003; 362: 1255-60
39. Leyland-Jones B, Semiglazov V, Pawlicki M et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving frst-line chemotherapy: a survival study. J Clin Oncol, 2005; 23: 5960-72
40. Wright JR, Ung YC, Julian JA et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol, 2007; 25: 1027-32
41. Kroger K, Weiland D, Ose C et al: Risk factors for venous thromboem-bolic events in cancer patients. Ann Oncol, 2006; 17: 297-303
42. Kakkar AK: Low-molecular-weight heparins: beyond thrombosis in the management of the cancer patient. Semin Thromb Hemost, 2003;29(Suppl.1): 13-15
43. Kakkar AK, Levine MN, Kadziola Z et al: Low molecular weight hepa-rin, therapy with dalteparin, and survival in advanced cancer: the frag-min advanced malignancy outcome study (FAMOUS). J Clin Oncol, 2004; 22: 1944-48
44. Solar P, Koval J, Mikes J et al: Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther, 2008; 7: 2263-71
45. Yildiz Y, YaylIm-Eraltan I, Arikan S et al: Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer? Arch Med Sci, 2010; 6: 932-36
46. Barbera L, Thomas G: Erythropoiesis stimulating agents, thrombosis and cancer. Radiotherapy and Oncology, 2010; 95: 269-76
47. Bielecka-Dabrowa A, Hannam S, Rysz J, Banach M: Malignancy-associated dyslipidemia. Open Cardiovasc Med J, 2011; 5: 35-40
48. Leo C, Horn LC, Rauscher C et al: Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res, 2006; 12: 6894-900
49. Heeschen C, Aicher A, Lehmann R et al: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 2003; 102: 1340-46
50. Rizzo JD, Somerfeld MR, Hagerty KL et al: American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and dar-bepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol, 2008; 26: 132-49
51. Buemi M, Cavallaro E, Floccari F et al: The pleiotropic effects of eryth-ropoietin in the central nervous system. J Neuropathol Exp Neurol, 2003; 62: 228-36
52. Rasmussen P, Foged EM, Krogh-Madsen R et al: Effects of erythropoi-etin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol, 2010; 109: 476-83
53. Lykissas MG, Korompilias AV, Vekris MD et al: The role of erythropoi-etin in central and peripheral nerve injury. Clin Neurol Neurosurg, 2007; 109: 639-44
54. Tsai PT, Ohab JJ, Kertesz N et al: A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci, 2006; 26: 1269-74
55. Campana WM, Myers RR: Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J, 2001; 15: 1804-6
56. Lipton SA: Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med, 2004; 350: 2516-17
57. Jerndal M, Forsberg K, Sena ES et al: A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab, 2010; 30: 961-68
58. Digicaylioglu M: Erythropoietin in stroke: quo vadis. Expert Opin Biol Ther, 2010; 10: 937-49
59. Westenfelder C: Unexpected renal actions of erythropoietin. Exp Nephrol, 2005; 10: 294-98
60. Bernhardt WM, Eckardt KU: Physiological basis for the use of erythro-poietin in critically ill patients at risk for acute kidney injury. Current Opinion in Critical Care, 2008; 14: 621-26
61. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Current Opinion in Nephrology and Hypertension, 2009; 18: 15-20
62. Gluba A, Banach M, Hannam S et al: The role of Toll-like receptors in renal diseases. Nat Rev Nephrol, 2010; 6: 224-35
63. Johnson DW, Pat B, Vesey DA et al: Delayed administration of darbe-poetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int, 2006; 69: 1806-13
64. Endre ZH, Walker RJ, Pickering JW et al: Early intervention with eryth-ropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int, 2010; 77: 1020-30
65. Małyszko JS, Rams L, Drozdowska-Rams L, Małyszko J: Serum neutro-phil gelatinase-associated lipocalin as a marker of kidney function in pregnancy - useful or doubtful? Arch Med Sci, 2010; 6: 744-47
66. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int, 2004; 66: 753-60
67. Faquin WC, Schneider TJ, Goldberg MA: Effect of infammatory cyto-kines on hypoxia-induced erythropoietin production. Blood, 1992; 79: 1987-94
68. Rysz J, Banach M, Cialkowska-Rysz A et al: Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemo-dialysis. Cell Mol Immunol, 2006; 3: 151-54
69. Rysz J, Aronow WS, Stolarek RS et al: Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets, 2009; 13: 541-50
70. El-Ters M, Muthyala U, Philipneri MD et al: Immune-complex deposits in "pauci-immune" glomerulonephritis: a case report and brief review of recent literature. Arch Med Sci, 2010; 6: 633-37
71. Vannucchi AM, Grossi A, Rafanelli D et al: Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol, 1994; 87: 18-23
72. Morceau F, Dicato M, Diederich M: Pro-Infammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis. Mediators Infamm, 2009; 2009: 405016
73. Woźniak B, Woźniak A, Drewa G et al: The effect of treatment on lipid peroxidation in patients with subarachnoid haemorrhage. Arch Med Sci, 2009; 5: 394-400
74. Barroso O, Mazzoni I, Rabin O: Hormone abuse, in sports: the antidop-ing perspective. Asian J Androl, 2008; 10: 391-402
75. Besarab A, Bolton WK, Browne JK et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med, 1998; 339: 584-90
76. Singh AK, Szczech L, Tang KL et al, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 2006; 355: 2085-98
77. Villa G: Erythropoiesis-stimulating agents: from the origins to new challenge. G Ital Nefrol, 2010; 27(Suppl.52): S38-46
78. Solomon SD, Uno H, Lewis EF et al: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med, 2010; 363: 1146-55
79. Lubas A, Zelichowski G, Próchnicka A et al: Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension. Arch Med Sci, 2010; 6: 533-38
80. Banach M, Kjeldsen SE, Narkiewicz K: Controversies in hypertension treatment. Curr Vasc Pharmacol, 2010; 8: 731-32
81. Ortega LM, Contreras G: The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: Beyond anaemia. Nefrologia, 2009; 29: 288-94
82. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recom-binant human erythropoietin on renal resistance vessels. Kidney Int, 1991; 39: 259-65
83. Dunn A, Lo V, Donnelly S: The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit. Am J Med Sci, 2007; 334: 65-71
84. Pratt MC, Lewis-Barned NJ, Walker RJ et al: Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol, 1992; 34: 363-65
85. Bartnicki P, Majewska E, Wilk R et al: Captopril and losartan modify mitogen-induced proliferative response and expression of some differentiation antigents on peripheral blood mononuclear cells in chronic uraemic patients. Arch Med Sci, 2009; 5: 401-7
86. Du J, Peng T, Scheidegger KJ, Delafontaine P: Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol, 1999; 19: 2119-26
87. Lundby C, Thomsen JJ, Boushel R et al: Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol, 2007; 578: 309-14
88. Williams B, Edmunds ME, Thompson JP et al: Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant, 1989; 4: 787-91
89. Krapf R, Hulter HN: Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). Clin J Am Soc Nephrol, 2009; 4: 470-80
90. Kedziora-Kornatowska K, Czuczejko J, Motyl J et al: Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Arch Med Sci, 2010; 6: 513-18
91. Casserly LF, Reddy SM, Dember LM: Venous thromboembolism in end-stage renal disease. Am J Kidney Dis, 2000; 36: 405-11
92. Jaar B, Denis A, Viron B et al: Effects of long-term treatment with re-combinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol, 1997; 17: 399-405
93. Krzeslowska J, Rysz J, Cierniewski CS, Luciak M: Expression of fbrino-gen receptors and GPIIb molecules on uraemic platelets: effect of re-combinant human erythropoietin therapy. Nephrol Dial Transplant, 1995; 10: 653-56
94. Diskin CJ, Stokes TJ, Thomas SG et al: An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron, 1998; 78: 365-68
95. Keung YK, Owen J: Iron defciency and thrombosis: literature review. Clin Appl Thromb Hemost, 2004; 10: 387-91
96. Henry DH, Dahl NV, Auerbach M et al: Intravenous ferric gluconate sig-nifcantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist, 2007; 12: 231-42
97. Pirnay F: Doping in sports. Rev Med Liege, 2001; 56: 265-68
98. Jeong SK, Cho YI, Duey M, Rosenson RS: Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther, 2010; 24: 151-60
99. Yu M, Wen N, Wenzhong Z et al: Effect of repeated ischaemic preconditioning on TLR4 and proinfammatory cytokines TNF-a and IL-1b in myocardial ischaemia-reperfusion injury in a rat model. Arch Med Sci, 2010; 6: 843-47
100. Okoński P, Banach M, Rysz J et al: L-arginine improves hemodynamic function and coronary fow in an experimental model of ischemia-re-perfusion injury. Ann Transplant, 2006; 11: 28-34
101. Haleagrahara N, Yee TM, Chakravarthi S, Lee N: Protective effect of N-acetylcysteine on cyclosporine A-induced changes in lipid hydroper-oxide levels and renal dysfunction in rats. Arch Med Sci, 2009; 5: 16-22
102. Covic A, Seica A, Gusbeth-Tatomir P, Goldsmith D: Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point? J Nephrol, 2008; 21: 478-84
103. Palmer SC, Navaneethan SD, Craig JC et al: Meta-analysis: erythropoi-esis-stimulating agents in patients with chronic kidney disease. Ann Intern Med, 2010; 153: 23-33
104. Liao D, Gong P, Li X et al: Co-culture with Schwann cells is an effective way for adipose-derived stem cells neural transdifferentiation. Arch Med Sci, 2010; 6: 145-51
105. Uyanikgil Y, Balcioglu HA: Neural stem cell therapy in neurological diseases. Arch Med Sci, 2009; 5: 296-302
106. Souvenir R, Fathali N, Ostrowski RP et al: Tissue inhibitor of matrix me-talloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia. Neurobiol Dis, 2011; 44(1): 28-37
107. Cicero AF, Ertek S: Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Arch Med Sci, 2010; 6: 469-77
108. Durmaz O, Demirkaya M, Sevinir B: Recombinant human erythropoi-etin b: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol, 2011; 28: 461-68